互動式分組討論

分組討論是基於許可、非正式的討論，讓成員可就特定主題交換想法和經驗並建立未來的合作關係。各場討論都會由主持人主持，主持人將負責引導討論的正常進行，並激發小組活力。為了充分利用這種形式，請準備好分享您自己的研究範例，參加小組解決問題的會議，並積極地分享您的想法。

所有分組討論均以現場形式進行。

BREAKOUTS WITH COFFEE:
MONDAY, AUGUST 11, 2025 | 9:35-10:20 AM

Bi & Multispecific Engineering
Bi and Multispecific T Cell Engagers in an Era of Increased Awareness of Tumor and Patient Heterogeneity
Moderator: Siddhartha Roychoudhury, PhD, Asset Leader, Immuno-Oncology Development, Astellas Pharma

• How do we go about selecting the right tumors for the right MOA?
• How can we explore novel approaches to MOA-driven patient enrichment?
• How can we develop options for rational combinations?

Breakthroughs in Cell Therapy
New Opportunities to Promote Tumor Antigen Presentation through Myeloid Cell Therapies
Moderator: Warren Anderson, PhD, Scientist III, Immunology, Inceptor Bio

• Recent technological advances have made concepts like tumor vaccines or transgenic TCRs more promising than ever. Can myeloid cell therapies perform similarly with reduced labor and cost?
• What have we learned thus far about the practical limitations of generating myeloid-based cell therapies? What has succeeded?
• Considering the successes of CAR Ts or T-cell directed therapies, how should we approach the idea of myeloid based cell therapies? Competitor or teammate?

Bridging Science and Support: Integrative Strategies in Cell Therapy
Moderator: David James, Resident Physician, Ric Scalzo Institute for Botanical Research, Naturopathic Specialists LLC

• Exploring how integrative and naturopathic oncology can support patients undergoing advanced immune therapies such as CAR T-cell, bispecific antibodies, NK cell vaccines, and dendritic cell therapy
• Clinical applications for monitoring immune therapy response and toxicity using biomarkers and interleukin profiling (e.g., IL-6, IL-8, IL-1β, VEGF, MMP9, TNF-α) from a patient-centered lens
• Practical strategies for managing treatment-related adverse events (cytokine release syndrome, neurotoxicity, fatigue) through evidence-informed supportive care
• Shared decision-making models to align complex therapies with patient values and quality-of-life goals
• Real-world insights into harmonizing conventional protocols with integrative care to improve outcomes and experience

Translating Multispecific Success
What Are We after with Bispecific Targeting of Solid Tumors?
Moderator: Tatiana Novobrantseva, PhD, CSO, NextPoint Therapeutics

• What unmet need is driving bispecific targeting? Efficacy? Width of applicability? Safety? What strategies are needed?
• Is there a special place for biparatopic targeting?
• Is companion diagnostic a must-have for developing bispecific targeting? Does it need to be quantitative?
• Bispecific versus combination: major pros and cons

BREAKOUTS WITH BREAKFAST:
WEDNESDAY, AUGUST 13, 2025 | 7:30-8:30 AM

Autoimmunity
Learnings from I-O for I&I
Moderator: Marc A. Gavin, PhD, Senior Research Fellow & Head, Immunology, InduPro

• Depleting pathogenic immune cells: Will TCEs be as potent as CAR T, within tolerated dose windows?
• KIR+ CD8 Tregs: Do they respond to current therapies, and does it matter?
• Agonizing cytokine receptors: Do feedback mechanisms make it too complicated?​

Antibody-Drug Conjugates
Selecting ADC Design Features for a Specific Target and Indication
Moderator: Ian Nessler, PhD, Senior Scientist II, Quantitative, Translational, and ADME Sciences, AbbVie

• Target Characterization: Expression and Internalization Profile
• Design Considerations for Heme vs. Solid Tumor Indications
• Payload Selection (Bystander vs. Non-Bystander Payloads)
• Future Directions and Novel ADC Formats

Innate Immunity
Translating in vitro Immuno-Oncology Models to in vivo Impact
Moderator: Craig Thalhauser, PhD, Senior Director, Clinical Pharmacology & Quantitative Sciences, Genmab US Inc

• What limits current in vitro models from accurately reflecting the complex tumor microenvironment and in vivo bispecific antibody activity?
• Designing in vitro assays that better predict targeted efficacy and potential for off-target effects within the TME
• Promising in vitro technologies for predicting in vivo bispecific antibody behavior

* 活動內容有可能不事先告知作更動及調整。